4. Danaher Corporation (NYSE:DHR)
Danaher Corporation is different from many biotech stocks because it is not a traditional drug developer. It is better understood as a picks-and-shovels player in the biotech and life sciences economy. While many biotech companies try to discover and commercialize medicines, Danaher provides the bioprocessing technologies, lab tools, consumables, filtration systems, chromatography resins, cell culture media, and manufacturing-related solutions that help the industry develop and produce therapeutics. That makes Danaher a more diversified and infrastructure-focused way to participate in the biotech sector.
The May 2026 watchlist described Danaher’s biotechnology segment as offering bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics. That is a critical point for investors. When drug developers invest in biologics, gene therapies, vaccines, advanced therapies, and manufacturing capacity, companies like Danaher may benefit from the broader spending cycle. In other words, Danaher does not need to depend on one single clinical trial result in the same way a smaller biotech company might. Its exposure is spread across the scientific and manufacturing backbone of the healthcare industry.
Danaher’s first-quarter 2026 results showed why the stock remains relevant in the biotech discussion. The company reported $6.0 billion in revenue, up 3.5% year over year, while non-GAAP core revenue increased 0.5%. Net earnings were $1.0 billion, or $1.45 per diluted common share, while non-GAAP adjusted diluted EPS grew 9.5% to $2.06. The company also produced $1.3 billion in operating cash flow and $1.1 billion in non-GAAP free cash flow, showing that this is not a speculative biotech story but a cash-generating life sciences and diagnostics company.
CEO Rainer M. Blair gave investors a direct explanation of the quarter, saying, “Our team executed well in the first quarter,” adding that Danaher was able to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth. He also noted that strength in bioprocessing and better-than-expected performance in life sciences largely offset the impact of a lighter-than-typical respiratory season at Cepheid. That sentence is important because it tells investors where the real strength came from: bioprocessing and life sciences, two areas closely tied to biotech research and therapeutic manufacturing.
Danaher also raised its full-year 2026 adjusted diluted EPS guidance to $8.35 to $8.55, compared with previous guidance of $8.35 to $8.50. That may look like a small adjustment, but in a market where healthcare tools companies have faced mixed demand, even a modest upward revision can help support investor confidence. The company’s planned acquisition of Masimo was also highlighted by management as a potential value-creating move, especially because Danaher believes it can use its operating system and global scale to improve performance.
For investors looking for biotech stocks to watch, life sciences stocks, bioprocessing stocks, and healthcare tools stocks, Danaher offers a more stable but still strategically important biotech angle. It may not deliver the same explosive move as a small company with a breakthrough clinical trial, but it gives exposure to the infrastructure side of medical innovation. The risk is that life sciences demand can soften when customers delay purchases, academic funding weakens, or diagnostics volumes slow. Still, Danaher’s free cash flow, scale, and bioprocessing exposure make it one of the more durable names for investors who want biotech exposure without betting everything on one drug approval.
Click next to see the following stock...
